Comparison of bevacizumab and ranibizumab in age-related macular degeneration: A systematic review and meta-Analysis

International Journal of Ophthalmology

Volumn 7, Issue 2, 2014, Pages 355-364

  Zhang, Xiao Yu ^a   Guo, Xiao Fan ^b   Zhang, Shao Dan ^a   He, Jing Na ^a   Sun, Cao Yu ^a   Zou, Yin ^a   Bi, Han Si ^a   Qu, Yang ^a  

^a Fourth People's Hospital of Shenyang   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Age related macular degeneration; Bevacizumab; Ranibizumab

Indexed keywords

EID: 84899845606     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2014.02.30     Document Type: Article

References (49)

1. Friedman DS, O'Colmain BJ, Muf10z B, Tom any SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 20045122(4):564-572. [PubMed]
2. Evans J, Worm aid R. Is the incidence of registrable age-related macular degeneration increasing? Br J Ophthalmol. 1996;8o(l):9-14. [PMCfree article] [PubMed]
3. VanNewkirk M, Weih LM, McCarty CA, Tayr HR. Cause-specific prevalence of bilateral visual impairment in Victoria, Australia: the visual impairment project. Ophthalmogy. 2001;l 08(53:960-967. [PubMed]
4. Resnikoff S, Pascolini D, Etya'aleD, Kocur I, Pararajasegaram R, Pokharel GP, Martti SP. G10bal data on visual impairment in the year 2002. Bull World Health Organ. 2004;82(ll):844-85l. [PMCfree article] [PubMed]
5. ChewEY, LindbladAS, ClemonsT. Summary results and recommendations from the age-related eye disease study. Arch Ophthalmol. 2009;l27(l2):l678-l679. [PMCfree article] [PubMed]
6. Chakravarthy U, WongTY, Fletcher A, Piault E, Evans C, Zlateva G, Buggage R, Pleil A, Mitchell P. Clinical risk factors for age-related macular degeneration: a systematic review and meta-Analysis. BMC Ophthalmol. 2010510:31. [PMCfree article] [PubMed]
7. Ferrara N,Gerber HP, LeCouter J. The bgy ofVEGFandits receptors. Nature Medicine. 2003;9(6):669-676. [PubMed]
8. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, De Jong PTVM. Increased expressn of anggenic growth factors in age-related macuathy. BrJ Ophthalmol. 1997581 (2):154-162. [PMCfree article] [PubMed]
9. Emerson MV, Lauer AK. Current and emerging therapies for the treatment of age-related macular degeneration. Clin Ophthalmol. 2008;2(2):377-388. [PMCfreearticle] [PubMed]
10. Kr011 P, Meyer CH. Which treatment is best for which AMD patient. BrJ Ophthalmol. 2006590(2) :l 28-130. [PMCfree article] [PubMed]
11. Gragoudas ES, Adam is AP, Cunningham ET, Jr., FeinsodM, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl JMed. 2004;35l(27):28O5-28l6. [PubMed]
12. Mir O, Alexandre J, Coriat R, Ropert S, Boudou-Rouquette P, Bui T, Chapron J, Durand JP, Dusser D, Goldwasser F. Safety of bevacizumab 7.5 mg/kg infusn over 10 minutes in NSCLCpatients. Invest New Drugs. 2012;3O(4):1756-I76o. [PubMed]
13. Yeung YA,Wu X, Reyes AE, 2nd, Vernes JM, Lien S, 10we J, Mai a M, Forrest WF, Meng YG, DamicoLA, Ferrara N, 10wman HB. A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. Cancer Res. 2010;7O(8):3269-3277. [PubMed]
14. Rosenfeld PJ, Moshfeghi AA, PuliafitoCA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36(4):33l-335. [PubMed]
15. Schmucker C, Ehlken C, Hansen LL, Antes G, Agostini HT, Lelgemann M. Intravitreal bevacizumab (Avastin) us ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. Curr Opin Ophthalmol. 2010;2l(3):2l8-226. [PubMed]
16. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(l4):l4l9-l43l. [PubMed]
17. Steinbrook R. The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med. 2006;355(14):409-1412. [PubMed]
18. Harvey KJ, Day RO, Campbell WG, Lipworth W. Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration? Med JAust. 2011;l94(ll):567-568. [PubMed]
19. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, JaffeGJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl JMed. 20115364(20):l897-1908. [PMCfree article] [PubMed]
20. JadadAR, Moore RA, Carr011 D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trialss blinding necessary? Con tred Clin Trial. 1996517(1) :l-12. [PubMed]
21. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-Analyses. Eur J Epideml. 2010;25(9):6O3-6O5. [PubMed]
22. Subramanian ML, Ness S,Abedi G, AhmedE, Daly M, Feinberg E, Bhatia S, Patel P, Nguyen M, Houranieh A. Bevacizumab us ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. Eye (nd) 2010;24(ll):l7O8-l7l5. [PubMed]
23. Chang TS, Kokame G, Casey R, Prenner J, Feiner L, Anderson N. Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration. Retina. 2009;29(9):l235-l24l. [PubMed]
24. Shah AR, Del Prre LV. Duration of action of intravitreal ranibizumab andbevacizumab in exudative AMD eyes based on macular volume measurements. Br JOphthalmol. 2009593(8) 11027-1032. [PubMed]
25. Landa G, AmdeW, Doshi V, Ali A, McGevna L, Gentile RC, Muldoon TO, Walsh JB, Rosen RB. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration. Ophthalmogica. 2009;223(6):37O-375. [PubMed]
26. Gamulescu MA, Radeck V, Lustinger B, Fink B, Helbig H. Bevacizumab versus ranibizumab in thetreatment of exudative age-related macular degeneration. Int Ophthalmol. 2010;3o(3):26l-266. [PubMed]
27. Fong DS, Custis P, Howes J, Hsu JW. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study. Ophthalmogy. 20l0;ll7(2):298-302. [PubMed]
28. Feng XF, Constable IJ, McAllister IL, Isaacs T. Comparison of visual acuity outcomes between ranibizumab and bevacizumab treatment in neovascular age-related macular degeneration. Int JOphthalmol. 201154(1):8s-88. [PMCfree article] [PubMed]
29. Biswas P, Sengupta S, Choudhary R, Home S, Paul A, Sinha S. Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration. Indian JOphthalmol. 2011;59(3):l9l-l96. [PMCfreearticle] [PubMed]
30. CarneiroAM, Barthelmes D, FalcaoMS, Mendonca LS, Fonseca SL, Goncalves RM, Faria-Correia F, Falcao-Reis FM. Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. Ophthalmogica. 2011;225(4):2ll-22l. [PubMed]
31. BelleriveC, Cinq-Mars B, La ndeG, Mai enfant M, Tourville E, Tardif Y, Giasson M, Hebert M. Bevacizumab and ranibizumab for neovascular age-related macular degeneration: a treatment approach based on individual patient needs. Can JOphthalmol. 2012;47(2):l6s-l69. [PubMed]
32. Martin DF, Maguire MG, Fine SL, Ying GS, JaffeGJ, Grunwald JE, Toth C, Redford M, Ferris FL., 3rd Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmogy. 2012;ll9(7):l388-l398. [PMCfreearticle] [PubMed]
33. Chakravarthy U, Harding SP, Rogers CA, Downes SM, tery AJ, Wordsworth S, Reeves BC. Ranibizumab versus bevacizumab to treat neovascular age-relatedmacular degeneration: one-year findings from the IVAN randomized trial. Ophthalmogy. 2012;ll9(7):l399-l4ll. [PubMed]
34. Sharma S, Johnson D, Abouammoh M, H011ands S, BrissetteA. Rate of serus adverse effects in a series of bevacizumab and ranibizumab injections. Can JOphthalmol. 2012547(3):275-279. [PubMed]
35. De Bats F, Grange JD, Cornut PL, Feldman A, Buriln C, Denis P, Kodjikian L. Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration: A retrospective study of 58 patients. J Fr Ophtalmol. 2012;35(9):66l-666. [PubMed]
36. Abouammoh M, Sharma S. Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration. Curr Opin Ophthalmol. 2011;22(3):l52-l58. [PubMed]
37. Van der Reis MI, La Heij EC, De Jong-Hesse Y, Ringens PJ, Hendrikse F, Schouten JS. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina. 2011;3l(8):l449- l469. [PubMed]
38. Zou L, Lai H, Zhou Q, XiaoF. Lasting controversy on ranibizumab andbevacizumab. Theranostics. 201151:395-402.[PMCfree article] [PubMed]
39. Chou R,Aronson N, Atkins D, Ismaila AS, Santaguida P, Smith DH, Whitick E,WiltTJ, Moher D. Assessing harms when comparing medical interventions: AHRQandthe Effective Health-Care Program. JClin Epideml. 2010;63(5):502-512. [PubMed]
40. Ladas ID, Karagiannis DA, Rouvas AA, Kotsolis A I, Ltsou A,Vergados I. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2000 injections. Retina. 2009;29(3):3l3-3l8. [PubMed]
41. Martinez-Carp10PA, Bonafonte-Morquez E, Heredia-Garcla CD, Bonafonte-RoyoS. Efficacy andsafety of intravitreal injection of bevacizumab in the treatment of neovascular glaucoma: systematic review. Arch Soc Esp Oftalmol. 2008;83(l0):579-588. [PubMed]
42. Brown D, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-relatedmacular degeneration: two-year results of theANCHOR study. Ophthalmogy. 2009;ll6(l):57-69. [PubMed]
43. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(l4):l4l9-l43l. [PubMed]
44. BashshurZF, Schakal A, Ham am RN, El Haibi CP, Jaafar RF, Noureddin BN. Intravitreal bevacizumab us verteporfin photodynamic therapy for neovascular age-relatedmacular degeneration. Arch Ophthalmol. 20075125 (103:1357-13 61. [PubMed]
45. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and a ne in choroidal neovascularization due to age-related macular degeneration. Ophthalmogy. 2007;ll4(6):ll79-ll85. [PubMed]
46. Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, 10keYK. A safety review and meta-Analyses of bevacizumab and ranibizumab: off-label versus goldstandard. P S One. 2012;(8):e4270l. [PMCfree article] [PubMed]
47. Magdelaine-Beuzelin C, Pinault C, PaintaudG, Watier H. Therapeutic antibodies in ophthalmogy: old is new again. MAbs. 2010;2(2):l76-l8o. [PMCfree article] [PubMed]
48. Singer MA, Cohen SR, Groth SL, Porbandarwalla S. Comparing bevacizumab and ranibizumab for initial reduction of central macular thickness in patients with retinal vein occlusns. Clin Ophthalmol. 201357:1377-1383. [PMCfree article] [PubMed]
49. Niederhauser N, Valmaggia C. Bevacizumab and ranibizumab for macular edema due to retinal vein occlusns. Klin Monbl Augenheilkd. 2013;23O(4):405-408. [PubMed]